Sign In
Buy JNJ
$231.29
+2.90 (+1.27%)
At Close: Jun 22, 2026
I Correctly Predicted That These 15 Dow Jones Stocks Would Boost Their Payouts in 2025. Here's Why It Can Happen Again in 2026.
02:15pm, Thursday, 22'nd Jan 2026
The Dow is chock-full of high-quality companies that pay growing dividends.
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
12:45pm, Thursday, 22'nd Jan 2026
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Abbott Labs Faces Setback with Q4 Revenue Miss and Cautious Guidance
11:14am, Thursday, 22'nd Jan 2026
Abbott Labs (ABT) experienced a significant drop in stock price after its Q4 earnings report, similar to the reaction seen with Johnson and Johnson (JNJ) followin
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:55am, Thursday, 22'nd Jan 2026
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Allstate Corp Grows Stock Holdings in Johnson & Johnson $JNJ
03:44am, Thursday, 22'nd Jan 2026
Allstate Corp increased its stake in Johnson and Johnson (NYSE: JNJ) by 1,554.7% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The
This 2.4%-Yielding Dividend King Remains As Healthy As Ever
01:45am, Thursday, 22'nd Jan 2026
Johnson & Johnson has increased its dividend each year for over half a century. The company has a very healthy financial profile.
Johnson & Johnson is doing 'great things for patients,' CFO says
12:15am, Thursday, 22'nd Jan 2026
Johnson & Johnson executive vice president and CFO Joseph Wolk discusses the company's performance and President Donald Trump's healthcare agenda on 'The Claman Countdown.' #fox #media #breakingnews #
PENSACOLA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- A U.S. District Court Special Master in the talc multidistrict litigation (MDL) against Johnson & Johnson (J&J) entered an Opinion, reaffirming that
Is This Dividend King Stock a Buy After a Major Development?
09:30pm, Wednesday, 21'st Jan 2026
Johnson & Johnson signed a deal to avoid tariffs. Although it faces other threats, it can overcome them.
Markets News, Jan. 21, 2026: Stocks End Sharply Higher as Trump Rules Out Force in Greenland, Backs Off Threat of New Tariffs
08:03pm, Wednesday, 21'st Jan 2026
Major stock indexes closed sharply higher Wednesday, a day after major equities indexes recorded their worst day in three months, as President Donald Trump appeared to rule out military force in Green
Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth
06:45pm, Wednesday, 21'st Jan 2026
Johnson & Johnson's MedTech segment saw its worldwide operational sales grow 5.4% year over year in 2025, reaching about $33.8 billion, the company said in a Wednesday (Jan. 21) earnings release. The
Johnson & Johnson (JNJ) Reports Q4 Earnings: What Key Metrics Have to Say
05:30pm, Wednesday, 21'st Jan 2026
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metri
Johnson & Johnson (JNJ) Tops Q4 Earnings and Revenue Estimates
05:20pm, Wednesday, 21'st Jan 2026
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.46 per share, beating the Zacks Consensus Estimate of $2.43 per share. This compares to earnings of $2.04 per share a year ago.
Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript
01:56pm, Wednesday, 21'st Jan 2026
Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript
AtaiBeckley seen as key beneficiary of Spravato's strong growth: Jefferies
01:00pm, Wednesday, 21'st Jan 2026
Jefferies analysts said the continued commercial momentum of Johnson & Johnson (NYSE:JNJ)'s Spravato (esketamine nasal spray) could provide a meaningful tailwind for the broader psychedelics sector, w
